Optimal serum calcidiol concentration for cancer prevention

Anticancer Research

Volumn 32, Issue 1 PART 2, 2012, Pages 373-381

  Tuohimaa, Pentti ^a   Lou, Y R ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Aging; Calcidiol; Calcitriol; Cancer; Chronic diseases; Prevention; Review; U shaped risk; Vitamin D

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; GLUCOCORTICOID; RETINOIC ACID RECEPTOR; SECALCIFEROL;

AGING; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CHRONIC KIDNEY DISEASE; COLON CANCER; CONFERENCE PAPER; ENZYME BLOOD LEVEL; ESOPHAGUS CANCER; HORMONE ACTION; HUMAN; HYPERVITAMINOSIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSTEOPOROSIS; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; ULTRAVIOLET B RADIATION;

CALCIFEDIOL; HUMANS; NEOPLASMS; VITAMINS;

EID: 84855988221     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (94)

1. Lips P van Schoor NM: The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab 25: 585-591, 2011.
2. Ruohola JP, Laaksi I, Ylikomi T, Haataja R, Mattila VM, Sahi T, Tuohimaa P and Pihlajamaki H: Association between serum 25(OH)D concentrations and bone stress fractures in Finnish young men. J Bone Miner Res 21: 1483-1488, 2006. (Pubitemid 44300055)
3. Vieth R: Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 69: 842-856, 1999.
4. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH and Weaver CM: Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96: 1911-1930, 2011.
5. Grimnes G, Joakimsen R, Figenschau Y, Torjesen PA, Almas B and Jorde R: The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass-a randomized controlled 1-year trial. Osteoporos Int 2011.
6. Tanaka H Seino Y: Direct action of 1,25-dihydroxyvitamin D on bone: VDRKO bone shows excessive bone formation in normal mineral condition. J Steroid Biochem Mol Biol 89-90: 343-345, 2004. (Pubitemid 38844308)
7. Bouillon R, Bischoff-Ferrari H and Willett W: Vitamin D and health: perspectives from mice and man. J Bone Miner Res 23: 974-979, 2008. (Pubitemid 351915717)
8. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D and Nicholson GC: Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303: 1815-1822, 2010.
9. Razzaque MS, Sitara D, Taguchi T, St-Arnaud R and Lanske B: Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. Faseb J 20: 720-722, 2006. (Pubitemid 46671193)
10. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka K, Sato H, Uchiyama Y, Masushige S, Fukamizu A, Matsumoto T and Kato S: Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 16: 391-396, 1997. (Pubitemid 27323308)
11. Tuohimaa P: Vitamin D, aging, and cancer. Nutr Rev 66: S147-152, 2008.
12. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ and Willett WC: Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98: 451-459, 2006.
13. Rimaniol JM, Authier FJ and Chariot P: Muscle weakness in intensive care patients: initial manifestation of vitamin D deficiency. Intensive Care Med 20: 591-592, 1994.
14. Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, Pihlajamaki H and Ylikomi T: An association of serum vitamin D concentrations <40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr 86: 714-717, 2007. (Pubitemid 47435839)
15. 3 as pluripotent immunomodulators. J Cell Biochem 88: 223-226, 2003.
16. Hypponen E, Laara E, Reunanen A, Jarvelin MR and Virtanen SM: Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358: 1500-1503, 2001. (Pubitemid 33055701)
17. 3 and its relation to physical activity and other heart disease risk factors in the general population. Ann Epidemiol 2: 697-703, 1992.
18. Scragg R, Jackson R, Holdaway IM, Lim T and Beaglehole R: Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 19: 559-563, 1990. (Pubitemid 20331800)
19. Schwartz GG: Multiple sclerosis and prostate cancer: what do their similar geographies suggest? Neuroepidemiology 11: 244-254, 1992.
20. Gloth FM, 3rd, Alam W and Hollis B: Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. J Nutr Health Aging 3: 5-7, 1999. (Pubitemid 129728788)
21. Kalueff AV, Keisala T, Minasyan A, Kuuslahti M, Miettinen S and Tuohimaa P: Behavioural anomalies in mice evoked by "Tokyo" disruption of the Vitamin D receptor gene. Neurosci Res 54: 254-260, 2006. (Pubitemid 43374442)
22. Zittermann A: Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 89: 552-572, 2003.
23. Guyton KZ, Kensler TW and Posner GH: Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev 61: 227-238, 2003. (Pubitemid 37259932)
24. Ylikomi T, Laaksi I, Lou YR, Martikainen P, Miettinen S, Pennanen P, Purmonen S, Syvala H, Vienonen A and Tuohimaa P: Antiproliferative action of vitamin D. Vitam Horm 64: 357-406, 2002. (Pubitemid 135763169)
25. Beer TM Myrthue A: Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther 3: 373-381, 2004. (Pubitemid 39193713)
26. Grant WB: A meta-analysis of second cancers after a diagnosis of nonmelanoma skin cancer: additional evidence that solar ultraviolet-B irradiance reduces the risk of internal cancers. J Steroid Biochem Mol Biol 103: 668-674, 2007.
27. Tuohimaa P, Pukkala E, Scelo G, Olsen JH, Brewster DH, Hemminki K, Tracey E, Weiderpass E, Kliewer EV, Pompe-Kirn V, McBride ML, Martos C, Chia KS, Tonita JM, Jonasson JG, Boffetta P and Brennan P: Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer 43: 1701-1712,2007. (Pubitemid 47049676)
28. de Vries E, Soerjomataram I, Houterman S, Louwman MW and Coebergh JW: Decreased risk of prostate cancer after skin cancer diagnosis: a protective role of ultraviolet radiation? Am J Epidemiol 165: 966-972, 2007. (Pubitemid 46536663)
29. Vieth R: How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. Anticancer Res 29: 3675-3684, 2009.
30. Luscombe CJ, Fryer AA, French ME, Liu S, Saxby MF, Jones PW and Strange RC: Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 358: 641-642, 2001. (Pubitemid 32786834)
31. Rowling MJ, Kemmis CM, Taffany DA and Welsh J: Megalin-mediated endocytosis of vitamin D binding protein correlates with 25- hydroxycholecalciferol actions in human mammary cells. J Nutr 136: 2754-2759, 2006. (Pubitemid 44771769)
32. 3. Biochemistry 7: 3317-3322, 1968.
33. Holick MF, Schnoes HK, DeLuca HF, Suda T and Cousins RJ: Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine. Biochemistry 10: 2799-2804, 1971.
34. 3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 9: 265-270, 2000.
35. Li J, Byrne ME, Chang E, Jiang Y, Donkin SS, Buhman KK, Burgess JR and Teegarden D: 1alpha, 25-Dihydroxyvitamin D hydroxylase in adipocytes. J Steroid Biochem Mol Biol 112: 122-126,2008.
36. van Driel M, Koedam M, Buurman CJ, Hewison M, Chiba H, Uitterlinden AG, Pols HA and van Leeuwen JP: Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. Faseb J 20: 2417-2419,2006.
37. Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80: 1678S-1688S, 2004.
38. Campbell FC, Xu H, El-Tanani M, Crowe P and Bingham V: The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol 79: 1-9, 2010.
39. Bikle DD Gee E: Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes. Endocrinology 124: 649-654, 1989. (Pubitemid 19057050)
40. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Meisen F, Christensen EI and Willnow TE: An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96: 507-515, 1999. (Pubitemid 29106838)
41. Adams JS: "Bound" to work: the free hormone hypothesis revisited. Cell 122: 647-649, 2005.
42. Bouillon R, Okamura WH and Norman AW: Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16: 200-257, 1995.
43. 3 is an active hormone in human primary prostatic stromal cells. The FASEB Journal 18: 332-334, 2004.
44. Lou YR, Molnar F, Perakyla M, Qiao S, Kalueff AV, St-Arnaud R, Carlberg C and Tuohimaa P: 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J Steroid Biochem Mol Biol 118: 162-170,2010.
45. 3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat 113: 31-41, 2009.
46. 3 are retained in growth plate cartilage cells from vitamin D receptor knockout mice. J Cell Biochem 90: 1207-1223,2003.
47. 3 enhance human osteoblast differentiation and mineralization. J Cell Biochem 99: 922-935, 2006.
48. St-Arnaud R, Arabian A and Naja R-P: CYP24A1, the 25-hydroxyvitamin D-24-hydroxylase, is necessary for optimal fracture repair. 14th Workshop on Vitamin D, Book of Abstracts: 54, 2009.
49. 3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. J Invest Dermatol 128: 2271-2280, 2008.
50. 3: its synthesis, biological activity and crystal structure with its receptor. PLoS ONE 6: e18124, 2011.
51. Tuohimaa P: Vitamin D and aging. J Steroid Biochem Mol Biol 114: 78-84, 2009.
52. Mizwicki MT Norman AW: The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signaling. Sci Signal 2: re4, 2009.
53. Shaffer PL Gewirth DT: Structural analysis of RXR-VDR interactions on DR3 DNA. J Steroid Biochem Mol Biol 89-90: 215-219,2004. (Pubitemid 38844285)
54. Seoane S Perez-Fernandez R: The vitamin D receptor represses transcription of the pituitary transcription factor Pit-1 gene without involvement of the retinoid X receptor. Mol Endocrinol 20: 735-748, 2006.
55. Shaffer PL Gewirth DT: Structural basis of VDR-DNA interactions on direct repeat response elements. EMBO J 21: 2242-2252, 2002. (Pubitemid 34516783)
56. Jurutka PW, MacDonald PN, Nakajima S, Hsieh JC, Thompson PD, Whitfield GK, Galligan MA, Haussler CA and Haussler MR: Isolation of baculovirus-expressed human vitamin D receptor: DNA responsive element interactions and phospho-rylation of the purified receptor. J Cell Biochem 85: 435-457, 2002. (Pubitemid 34274910)
57. Koszewski NJ, Reinhardt TA and Horst RL: Differential effects of 20-epi vitamin D analogs on the vitamin D receptor homodimer. J Bone Miner Res 14: 509-517, 1999. (Pubitemid 29153383)
58. Nishikawa J, Kitaura M, Matsumoto M, Imagawa M and Nishihara T: Difference and similarity of DNA sequence recognized by VDR homodimer and VDR/RXR heterodimer. Nucleic Acids Res 22: 2902-2907, 1994.
59. Marshall TG: Are statins analogues of vitamin D? Lancet 368: 1234; author reply 1235, 2006.
60. Garland CF, Garland FC and Gorham ED: Can colon cancer incidence and death rates be reduced with calcium and vitamin D? Am J Clin Nutr 54: 193S-201S, 1991.
61. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK and Gorham ED: Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study [see comments]. Lancet 2: 1176-1178, 1989. (Pubitemid 19275448)
62. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Halimans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M and Hakama M: Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108: 104-108, 2004. (Pubitemid 37444451)
63. Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K and Tangrea JA: Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 16: 2784-2786, 2007. (Pubitemid 351196338)
64. Goodwin PJ: Vitamin D in cancer patients: above all, do no harm. J Clin Oncol 27: 2117-2119, 2009.
65. Muenstedt K El-Safadi S: Nutritive Supplements - Help or Harm for Breast Cancer Patients? Breast Care (Basel) 5: 383-387,2010.
66. Chen W, Dawsey SM, Qiao YL, Mark SD, Dong ZW, Taylor PR, Zhao P and Abnet CC: Prospective study of serum 25(OH)-vitamin D concentration and risk of oesophageal and gastric cancers. Br J Cancer 97: 123-128, 2007. (Pubitemid 47012092)
67. Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J and Albanes D: A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 66: 10213-10219, 2006. (Pubitemid 44672077)
68. IARC: Vitamin D and Cancer. IARC Working Group Reports 52008.
69. Michaelsson K, Baron JA, Snellman G, Gedeborg R, Byberg L, Sundstrom J, Berglund L, Arnlov J, Hellman P, Blomhoff R, WoIk A, Garmo H, Holmberg L and Melhus H: Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr 92: 841-848, 2010.
70. Stumpf WE: The dose makes the medicine. Drug Discov Today 11: 550-555, 2006.
71. Melamed ML, Michos ED, Post W and Astor B: 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168: 1629-1637, 2008.
72. Visser M, Deeg DJ, Puts MT, Seidell JC and Lips P: Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr 84: 616-622; quiz 671-612, 2006.
73. Querfeld U Mak RH: Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window. Pediatr Nephrol 25: 2413-2430, 2010.
74. Razzaque MS: The dualistic role of vitamin D in vascular calcifications. Kidney Int 79: 708-714, 2011.
75. Bodnar LM, Catov JM, Zmuda JM, Cooper ME, Parrott MS, Roberts JM, Marazita ML and Simhan HN: Maternal serum 25-hydroxyvitamin D concentrations are associated with small-for-gestational age births in white women. J Nutr 140: 999-1006, 2010.
76. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C and Demay M: Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 29: 726-776, 2008.
77. McGrath JJ, Eyles DW, Pedersen CB, Anderson C, Ko P, Burne TH, Norgaard-Pedersen B, Hougaard DM and Mortensen PB: Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch Gen Psychiatry 67: 889-894,2010.
78. McGrath JJ, Saha S, Burne TH and Eyles DW: A systematic review of the association between common single nucleotide polymorphisms and 25-hydroxyvitamin D concentrations. J Steroid Biochem Mol Biol 121: 471-477, 2010.
79. Brookes EB Morrison AW: Vitamin D deficiency and deafness. Br Med J (Clin Res Ed) 283: 273-274, 1981.
80. Brookes GB: Vitamin D deficiency - a new cause of cochlear deafness. J Laryngol Otol 97: 405-420, 1983.
81. Brookes GB: Vitamin D deficiency and deafness: 1984 update. Am J Otol 6: 102-107, 1985.
82. Cohen HN, Fogelman I, Boyle IT and Doig JA: Deafness due to hypervitaminosis D. Lancet 1: 985, 1979. (Pubitemid 9163680)
83. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR and Heaney RP: Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85: 1586-1591,2007. (Pubitemid 46890428)
84. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O'Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, Khandekar J and Hubbell FA: Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100: 1581-1591, 2008.
85. Haussler MR: Vitamin D receptors: nature and function. Annu Rev Nutr 6: 527-562, 1986.
86. 3 production. Am J Physiol 258: E780-789, 1990.
87. 3 and total 24,25-dihydroxyvitamin D in human serum. Ann Clin Res 13: 26-33, 1981.
88. Wagner D, Hanwell HE, Schnabl K, Yazdanpanah M, Kimball S, Fu L, Sidhom G, Rousseau D, Cole DE and Vieth R: The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) response to vitamin D(3) supplementation. J Steroid Biochem Mol Biol 126: 72-77, 2011.
89. Bischoff-Ferrari HA: Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 624: 55-71, 2008.
90. Hathcock JN, Shao A, Vieth R and Heaney R: Risk assessment for vitamin D. Am J Clin Nutr 85: 6-18, 2007. (Pubitemid 46067609)
91. 3 do the elderly need? J Am Coll Nutr 25: 429-435, 2006.
92. Garland CF, Gorham ED, Mohr SB and Garland FC: Vitamin D for cancer prevention: global perspective. Ann Epidemiol 19: 468-483, 2009.
93. Ross AC, Taylor CL, Yaktine AL and Del Valle HB: Dietary reference intakes for calcium and vitamin D. National Academic Press: 1-1115, 2010.
94. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ and Shapses SA: The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96: 53-58, 2011.